Equities Analysts Set Expectations for ALLR Q1 Earnings

Allarity Therapeutics, Inc. (NASDAQ:ALLR) – Investment analysts at Ascendiant Capital Markets issued their Q1 2027 earnings per share (EPS) estimates for shares of Allarity Therapeutics in a report issued on Thursday, April 9th. Ascendiant Capital Markets analyst E. Woo expects that the company will post earnings of ($0.24) per share for the quarter. Ascendiant Capital Markets currently has a “Buy” rating and a $9.75 target price on the stock. The consensus estimate for Allarity Therapeutics’ current full-year earnings is ($78.08) per share. Ascendiant Capital Markets also issued estimates for Allarity Therapeutics’ Q2 2027 earnings at ($0.24) EPS, Q3 2027 earnings at ($0.24) EPS, Q4 2027 earnings at ($0.24) EPS and FY2027 earnings at ($0.97) EPS.

Allarity Therapeutics (NASDAQ:ALLR) last announced its quarterly earnings data on Monday, March 30th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.01.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allarity Therapeutics in a report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Allarity Therapeutics currently has a consensus rating of “Hold” and an average target price of $9.75.

Allarity Therapeutics Price Performance

ALLR stock opened at $1.19 on Tuesday. The firm has a market cap of $18.83 million, a price-to-earnings ratio of -1.49 and a beta of 0.01. Allarity Therapeutics has a 1-year low of $0.70 and a 1-year high of $2.35. The firm has a fifty day moving average price of $1.07 and a two-hundred day moving average price of $1.18.

Institutional Investors Weigh In On Allarity Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Private Advisor Group LLC bought a new stake in Allarity Therapeutics in the third quarter valued at $441,000. Renaissance Technologies LLC grew its position in shares of Allarity Therapeutics by 274.1% during the fourth quarter. Renaissance Technologies LLC now owns 247,612 shares of the company’s stock worth $267,000 after acquiring an additional 181,426 shares during the last quarter. DRW Securities LLC acquired a new stake in shares of Allarity Therapeutics in the 4th quarter worth about $133,000. Capital Advisors Inc. OK acquired a new stake in shares of Allarity Therapeutics in the 4th quarter worth about $108,000. Finally, Citadel Advisors LLC bought a new stake in Allarity Therapeutics in the 3rd quarter valued at about $149,000. 11.53% of the stock is owned by institutional investors and hedge funds.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.